{"doi":"10.1016/j.jval.2016.09.1682","title":"Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Non-Valvular Atrial Fibrillation","abstract":null,"journal":"Value in Health","year":2016,"id":622966,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1609859,"name":"AR Shewale","orcid":null,"position":1,"is_corresponding":false},{"id":1609860,"name":"J Talbert","orcid":null,"position":2,"is_corresponding":false},{"id":1530123,"name":"J Brown","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Non-Valvular Atrial Fibrillation","abstract":null,"is_dataset_classified":null,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19910364","pmcid":null,"openalex_id":"https://openalex.org/W2543625995","authors":[],"funders":[],"total_grants":0,"fwci":0.6234,"citation_percentile":0.74240055,"influential_citations":0,"citation_trend":[{"year":2016,"count":1},{"year":2018,"count":2},{"year":2022,"count":1}],"oa_status":"closed","license":"https://www.elsevier.com/open-access/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S1098301516330480?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1098301516330480?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.jval.2016.09.1682","host_type":"journal"}],"fields_of_study":["Atrial Fibrillation Management and Outcomes"],"mesh_terms":[],"keywords":["Dabigatran","Apixaban","Rivaroxaban","Medicine","Atrial fibrillation","Internal medicine","Stroke (engine)","Warfarin","Cardiology"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T21:45:12.354246Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}